ELITE II and Val-HeFT are different trials: together what do they tell us?
AUTOR(ES)
Dickstein, Kenneth
FONTE
BioMed Central
RESUMO
The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The trials differed, however, in terms of their primary hypothesis, study design, and treatment regimens, and this must be taken into consideration when comparing and interpreting the data from these studies. The data are in many ways complementary, and add to our understanding of the optimal treatment of symptomatic heart failure. Additional studies are needed, however, to fully define the role of angiotensin II receptor antagonists in the management of this very heterogeneous group of patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=59523Documentos Relacionados
- Idiotypes and anti-idiotypes: what are they trying to tell us?
- Biomarkers in first-degree relatives of patients with bipolar disorder: what can they tell us?
- The observed global warming record: What does it tell us?
- Drug development for cryptococcosis treatment: what can patents tell us?
- DNA repair diseases: what do they tell us about cancer and aging?
